NICOLE ANTAO: Open Payments
NPI 1942450986 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,145 in 106 payments from 20 companies in 2025. Trend: 2023 $444 · 2024 $819 · 2025 $2,145
Food & beverage: $2,142Education: $3
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 19 | $339 |
| GENZYME CORPORATION | 12 | $272 |
| AstraZeneca Pharmaceuticals LP | 12 | $232 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $207 |
| Insmed, Inc. | 8 | $151 |
| Regeneron Healthcare Solutions, Inc. | 7 | $140 |
| Grifols USA, LLC | 6 | $121 |
| Viatris Specialty LLC | 6 | $100 |
| ABBVIE INC. | 3 | $94 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $86 |
Products named: DUPIXENT, NUCALA, GLASSIA, TEZSPIRE, Arikayce, Prolastin-C Liquid, YUPELRI, TRELEGY ELLIPTA.
Industry payments across IN — which companies pay providers there.
